Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Gross Margin (2016 - 2025)

CorMedix (CRMD) has disclosed Gross Margin for 12 consecutive years, with 83.43% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 1280.0% to 83.43% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 88.46% through Dec 2025, down 422.0% year-over-year, with the annual reading at 88.46% for FY2025, 420.0% down from the prior year.
  • Gross Margin hit 83.43% in Q4 2025 for CorMedix, down from 89.26% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 8322.71% in Q1 2024 to a low of 76.12% in Q2 2021.
  • Historically, Gross Margin has averaged 579.52% across 4 years, with a median of 86.35% in 2025.
  • Biggest five-year swings in Gross Margin: surged 17456bps in 2022 and later tumbled -822680bps in 2025.
  • Year by year, Gross Margin stood at 14.88% in 2021, then surged by 563bps to 98.63% in 2022, then fell by -2bps to 96.24% in 2024, then fell by -13bps to 83.43% in 2025.
  • Business Quant data shows Gross Margin for CRMD at 83.43% in Q4 2025, 89.26% in Q3 2025, and 95.31% in Q2 2025.